Browse Correction
Filter Results
- By Specialty
- All Specialties
- Infectious Disease (27)
- Cardiology (22)
- Hematology/Oncology (19)
-
Pulmonary/
Critical Care (13) - Endocrinology (12)
- Obstetrics/Gynecology (12)
- Pediatrics (12)
- Gastroenterology (11)
- Genetics (7)
- Nephrology (5)
- Neurology/Neurosurgery (5)
- Psychiatry (4)
- Geriatrics/Aging (3)
- Allergy/Immunology (2)
- Dermatology (2)
- Emergency Medicine (2)
- Medical Ethics (2)
- Surgery (2)
- Medical Practice, Training, and Education (1)
- Ophthalmology (1)
- Orthopedics (1)
- Rheumatology (1)
- By Date
- Past 10 years
- Past 20 years
- Past 50 years
- Past 100 years
- Complete archive (1812-present)
- Specific date range
Sort By:
- Newest
- Oldest
- Most Viewed
- Most Cited
Correspondence
Veterans Affairs Diabetes Trial — Corrections
To the Editor: The Supplementary Appendix in which we provided additional information related to our article (Jan. 8 issue) contains some errors. In both Appendix 1 and Appendix 2, the heading "6 Year Event Rate" should have read "6-Year Event-free Rate." We thank the reader who detected this error.…
- Free Full Text
Correspondence
Serotonin Rising
To the Editor: Rosen's Perspective article (March 5 issue) highlights recent findings that gut-derived serotonin inhibits bone formation by stimulating serotonin receptors on the preosteoblast. A critical question is whether serotonin is delivered to bone in some blood element or as free plasma…
- Free Full Text
Correspondence
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
To the Editor: Gnant et al. (Feb. 12 issue) report on the Austrian Breast and Colorectal Cancer Study Group trial 12 (ABCSG-12) (ClinicalTrials.gov number, NCT00295646), which looked at the use of goserelin plus either tamoxifen or anastrozole with or without zoledronic acid in premenopausal women…
- Free Full Text
Correspondence
Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet
To the Editor: How do Shai et al. (July 17 issue) explain why the subjects in their study regained weight between month 6 and month 24, despite a reported reduction of 300 to 600 calories per day? Contributing possibilities may include the notion that a food-frequency questionnaire cannot precisely…
- Free Full Text
Correspondence
Graves' Disease
To the Editor: In his Clinical Practice article on Graves' disease, Brent (June 12 issue) comments on the combined use of antithyroid drugs and radioiodine and refers to the results of our trial, showing no effects of antithyroid drugs on radioiodine therapy after a 3-day-withdrawal. However, in a…
- Free Full Text
Correspondence
Eltrombopag in Thrombocytopenia
To the Editor: McHutchison et al. (Nov. 29 issue) report that eltrombopag (a thrombopoietin-receptor agonist) raises the platelet count in patients with hepatitis C cirrhosis and thrombocytopenia. Its application in treating interferon-induced thrombocytopenia, however, necessitates that it improve…
- Free Full Text
Correspondence
Maternal Thyroid Deficiency during Pregnancy and Subsequent Neuropsychological Development of the Child
To the Editor: Haddow et al. (Aug. 19 issue) suggest that screening pregnant women for hypothyroidism by measuring serum thyrotropin may be worthwhile and that treating women with serum thyrotropin concentrations at or above the 98th percentile could lead to "an increase of approximately 4 points…
- Free Full Text
Correspondence
Therapy for Hyperthyroidism and Graves' Ophthalmopathy
To the Editor: The article by Bartalena et al. (Jan. 8 issue) on therapy for hyperthyroidism and Graves' ophthalmopathy could be important in establishing practice precedents. Clarification of the following points is needed to define more fully the inferences readers can draw from the findings. We…
- Free Full Text
Correspondence
Obesity
To the Editor: In their article on obesity, Rosenbaum et al. (Aug. 7 issue) characterize sibutramine, currently undergoing regulatory review as a drug for the treatment of obesity, as having both catecholaminergic and serotonergic agonist effects. Sibutramine, in fact, is not an agonist at…
- Free Full Text
Correspondence
Correction and Revision of Conclusions — Dietary Trends in the United States
To the Editor: The article by Popkin et al. (Sept. 5, 1996, issue) on dietary trends presents a potentially misleading picture of fruit and vegetable intake in the United States. The implied serving sizes (grams of dietary intake in Table 4 of the article divided by numbers of servings in Table 3)…
- Free Full Text
Correspondence
Alendronate in Postmenopausal Osteoporosis
To the Editor: The study by Liberman et al. (Nov. 30 issue) on the effects of alendronate on bone mineral density and the incidence of fractures in postmenopausal women with osteoporosis is important, but in our view not as exciting as it first seems. The authors pooled the results for women and,…
- Free Full Text
Correspondence
Additional Corrections: Interferon for Hemangiomas of Infancy
To the Editor: Inaccuracies in our paper "Interferon Alfa-2a Therapy for Life-Threatening Hemangiomas of Infancy" prompted a careful review. On the basis of our reanalysis and an interim review by a standing faculty committee of the Harvard Medical School, we submitted a revised Table 1, published…
- Free Full Text
Page
- 1
